Results 51 to 60 of about 1,054 (155)

Rimegepant in airplane headache treatment: a case report

Journal of Medical Case Reports
Airplane headache is a rare condition first identified in 2004 and subsequently included in the International Classification of Headache Disorders (Headache Classification Committee of the International Headache Society in Cephalalgia 33:629-808, 2013. https://doi.org/10.1177/0333102413485658 ). Airplane headache typically presents as intense, stabbing,
Autunno, Massimo, De Luca, Marcella, Ferraù, Ludovica, Rodolico, Carmelo   +3 more
openaire   +4 more sources

CGRP‐Targeted Therapy in Vestibular Migraine—How Strong Is the Evidence?

European Journal of Neurology, Volume 33, Issue 7, July 2026.
ABSTRACT Background Medications for migraine prevention targeting the calcitonin gene‐related peptide (CGRP) pathway have substantially reduced symptom burden in many patients that have failed previous treatment strategies. In contrast, data on treatment response to monoclonal antibodies (mAbs) or small molecule receptor antagonists (gepants) in ...
Alexander Andrea Tarnutzer, Patricia Castro Abarca, Diego Kaski   +2 more
wiley   +1 more source

Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectives

Expert Review of Neurotherapeutics
Migraine is among the most disabling neurological disorders worldwide and preventive treatment remains a cornerstone for reducing disease burden. Recent advances in mechanism-based therapies have positioned calcitonin gene-related peptide (CGRP) and its main receptor as central targets for migraine prophylaxis.This updated narrative overview summarizes
Lanfranco Pellesi, Damiana Scuteri, Paolo Martelletti   +2 more
openaire   +2 more sources

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 7, Page 1525-1536, July/August 2026.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi, Cristina Tassorelli, Manjit Matharu, Taoufik Alsaadi, Carlos Vallarino, Lars Viktrup, Maurice Vincent, Rebecca L. Robinson   +7 more
wiley   +1 more source

Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study

Brain Sciences
Objectives: The present open-label multicenter pilot study sought to prospectively evaluate the efficacy and safety of rimegepant in treating migraine attacks.
Emmanouil V. Dermitzakis, Dimitrios Rikos, Michail Vikelis, Georgia Xiromerisiou, Styliani Zisopoulou, Dimitrios Rallis, Panagiotis Soldatos, George S. Vlachos, Georgios G. Vasiliadis, Andreas A. Argyriou   +9 more
doaj   +1 more source

Comparative efficacy, safety, and number needed to treat analysis of atogepant and rimegepant for the preventive treatment of episodic migraine in Japanese participants: An indirect comparison analysis

Cephalalgia Reports
Background In the absence of head-to-head analyses, indirect treatment comparisons (ITCs) can be used for comparative treatment evaluations. A previous ITC of atogepant and rimegepant assessed outcomes from US trials for the preventive treatment of ...
Takao Takeshima, Yasuhiko Matsumori, Gina Ahmadyar, Pranav Gandhi, Kari Kelton, Toru Yamazaki, Karen Carr, Krisztian Nagy, Jessica Ailani   +8 more
doaj   +1 more source

Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults

CPT: Pharmacometrics & Systems Pharmacology
Rimegepant is a small‐molecule calcitonin gene‐related peptide receptor antagonist approved for acute and preventive migraine treatment in adults, administered as an orally disintegrating tablet (ODT).
Craig M. Comisar, Jim H. Hughes, Jose Francis, Yorinao Chinda, Yamato Sano, Chieko Muto, Christine Neumar, Rajinder Bhardwaj, Richard Bertz, Jing Liu   +9 more
doaj   +1 more source

Human Radiolabeled Mass Balance Studies Supporting New Drugs Approved by FDA Between 2019 and 2023

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
Anuradha Ramamoorthy, Alana Chen, Edwin Chiu Yuen Chow, Daphne Guinn, Anjali Iyer, Sonia Pahwa, Yunzhao Ren, Chinmay Shukla, Suresh Doddapaneni, Zhixia Yan Danielsen   +9 more
wiley   +1 more source

Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

Journal of Pain Research
Richard B Lipton,1 Alexandra Thiry,2 Beth A Morris,3 Robert Croop3 1Department of Neurology and the Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, NY, USA; 2Biostatistics, Pfizer, Inc., New York, NY, USA; 3Clinical Operations (BM)
Lipton RB, Thiry A, Morris BA, Croop R
doaj  

Exosomes from mesenchymal stem/stromal cells and their therapeutic role in osteoarthritic pain

Journal of Experimental Orthopaedics, Volume 13, Issue 3, July 2026.
Dimitrios Kouroupis, Stanislava Jergova, Jacqueline Sagen, Thomas M. Best   +3 more
wiley   +1 more source